What is Zacks Research’s Estimate for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research raised their Q4 2024 earnings per share (EPS) estimates for Exelixis in a research note issued to investors on Monday, December 16th. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of $0.37 per share for the quarter, up from their prior estimate of $0.36. The consensus estimate for Exelixis’ current full-year earnings is $1.69 per share. Zacks Research also issued estimates for Exelixis’ Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.57 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.49 EPS and FY2026 earnings at $2.14 EPS.

EXEL has been the topic of a number of other reports. JMP Securities restated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Friday, October 11th. Guggenheim upped their price objective on Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their target price on Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Royal Bank of Canada restated an “outperform” rating and set a $34.00 price target on shares of Exelixis in a report on Wednesday, October 30th. Finally, Piper Sandler lifted their price objective on shares of Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.88.

Exelixis Stock Up 0.4 %

Exelixis stock traded up $0.14 during mid-day trading on Thursday, reaching $33.80. 77,320 shares of the company’s stock traded hands, compared to its average volume of 2,048,067. Exelixis has a 12-month low of $19.20 and a 12-month high of $36.97. The stock has a 50 day moving average of $33.20 and a two-hundred day moving average of $27.43. The company has a market cap of $9.65 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 0.89 and a beta of 0.52.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares of the company’s stock, valued at approximately $9,828,514.55. This represents a 3.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now owns 605,325 shares in the company, valued at approximately $15,968,473.50. This represents a 3.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 339,736 shares of company stock valued at $11,508,610. 2.85% of the stock is currently owned by company insiders.

Institutional Trading of Exelixis

A number of hedge funds have recently bought and sold shares of the stock. Covestor Ltd raised its position in shares of Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 341 shares in the last quarter. Resonant Capital Advisors LLC lifted its position in shares of Exelixis by 3.6% during the second quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock valued at $309,000 after buying an additional 477 shares during the last quarter. Cornercap Investment Counsel Inc. boosted its holdings in shares of Exelixis by 1.1% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock valued at $1,135,000 after buying an additional 539 shares in the last quarter. Creative Planning boosted its holdings in shares of Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock valued at $1,611,000 after buying an additional 548 shares in the last quarter. Finally, Advisors Asset Management Inc. grew its position in shares of Exelixis by 3.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock worth $515,000 after buying an additional 609 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.